{"id":27806,"date":"2026-02-06T10:45:37","date_gmt":"2026-02-06T10:45:37","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=27806"},"modified":"2026-02-06T10:45:37","modified_gmt":"2026-02-06T10:45:37","slug":"eisai-and-henlius-sign-japan-rights-deal-for-serplulimab","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/","title":{"rendered":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d8\u30f3\u30ea\u30a2\u30b9\u304cSerplulimab\u306e\u65e5\u672c\u306b\u304a\u3051\u308b\u6a29\u5229\u5951\u7d04\u3092\u7de0\u7d50"},"content":{"rendered":"

\u30a8\u30fc\u30b6\u30a4\u682a\u5f0f\u4f1a\u793e\uff08\u672c\u793e\uff1a\u6771\u4eac\u90fd\u3001\u793e\u9577\uff1a\u5185\u85e4\u6674\u592b\u3001\u4ee5\u4e0b\u300c\u30a8\u30fc\u30b6\u30a4\u300d\uff09\u3068\u4e0a\u6d77\u30d8\u30f3\u30ea\u30a2\u30b9\u30fb\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u793e\uff08\u672c\u793e\uff1a\u4e2d\u56fd\u4e0a\u6d77\u5e02\u3001\u793e\u9577\uff1a\u5289\u6167\u6167\u3001\u4ee5\u4e0b\u300c\u30d8\u30f3\u30ea\u30a2\u30b9\u30fb\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u793e\u300d\uff09\u306f\u3001\u6297PD 1\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u30bb\u30eb\u30d7\u30ea\u30de\u30d6\u306b\u3064\u3044\u3066\u3001\u65e5\u672c\u306b\u304a\u3051\u308b\u72ec\u5360\u7684\u5546\u696d\u5316\u5951\u7d04\u304a\u3088\u3073\u5171\u540c\u72ec\u5360\u7684\u958b\u767a\u30fb\u88fd\u9020\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002\u672c\u5951\u7d04\u306b\u3088\u308a\u3001\u30a8\u30fc\u30b6\u30a4\u306f\u672c\u5264\u3092\u65e5\u672c\u5e02\u5834\u3067\u5546\u696d\u5316\u3059\u308b\u6a29\u5229\u3092\u7372\u5f97\u3057\u3001\u958b\u767a\u30fb\u88fd\u9020\u306e\u8cac\u4efb\u306f\u30e9\u30a4\u30bb\u30f3\u30b9\u6761\u4ef6\u306b\u57fa\u3065\u3044\u3066\u5206\u62c5\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002.<\/p>\n

\u30bb\u30eb\u30d7\u30ea\u30de\u30d6\u306f\u30d8\u30f3\u30ea\u30a6\u30b9\u793e\u304c\u958b\u767a\u3057\u305f\u6b21\u4e16\u4ee3\u306e\u6297PD 1\u6297\u4f53\u3067\u3059\u3002\u540c\u30af\u30e9\u30b9\u306e\u65e2\u5b58\u85ac\u3068\u306f\u7d50\u5408\u30e1\u30ab\u30cb\u30ba\u30e0\u304c\u7570\u306a\u308a\u307e\u3059\u3002\u4e2d\u56fd\u3067\u306f\u3001\u3059\u3067\u306b\u8907\u6570\u306e\u304c\u3093\u9069\u5fdc\u3067\u627f\u8a8d\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u975e\u5c0f\u7d30\u80de\u80ba\u6241\u5e73\u4e0a\u76ae\u764c\u3001\u5e83\u7bc4\u56f2\u5c0f\u7d30\u80de\u80ba\u764c\u3001\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3001\u98df\u9053\u6241\u5e73\u4e0a\u76ae\u764c\u306a\u3069\u3067\u3059\u3002\u6b27\u5dde\u9023\u5408\uff08EU\uff09\u3067\u306f\u3001\u30bb\u30eb\u30d7\u30ea\u30de\u30d6\u306f\u30d8\u30c8\u30ed\u30cb\u30d5\u30e9\u30a4\u306e\u540d\u3067\u8ca9\u58f2\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u6297PD 1\u6297\u4f53\u306f\u3001\u5e83\u7bc4\u306a\u75c5\u671f\u306e\u5c0f\u7d30\u80de\u80ba\u304c\u3093\u3092\u9069\u5fdc\u75c7\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u3066\u304a\u308a\u3001\u3053\u306e\u9069\u5fdc\u75c7\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u85ac\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u305f\u4e16\u754c\u521d\u306e\u6297PD 1\u6297\u4f53\u3068\u3057\u3066\u6ce8\u76ee\u3055\u308c\u3066\u3044\u307e\u3059\u3002.<\/p>\n

\u65e5\u672c\u3067\u306f\u73fe\u5728\u3001\u5e83\u7bc4\u306a\u30b9\u30c6\u30fc\u30b8\u306e\u5c0f\u7d30\u80de\u80ba\u304c\u3093\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c\u2161\u76f8\u9023\u95a2\u8a66\u9a13\u3092\u5b9f\u65bd\u4e2d\u3002\u305d\u306e\u7d50\u679c\u306b\u57fa\u3065\u304d\u30012026\u5e74\u5ea6\u306b\u627f\u8a8d\u7533\u8acb\u3092\u884c\u3046\u4e88\u5b9a\u3067\u3059\u3002\u3053\u306e\u7533\u8acb\u306b\u306f\u3001\u65e5\u672c\u3067\u306e\u9023\u95a2\u8a66\u9a13\u306e\u30c7\u30fc\u30bf\u3068\u3001\u4e2d\u56fd\u3068\u6b27\u5dde\u3067\u306e\u627f\u8a8d\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u305f\u7b2cIII\u76f8\u81e8\u5e8a\u8a66\u9a13\u30c7\u30fc\u30bf\u304c\u4f7f\u7528\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002\u540c\u6642\u306b\u3001\u975eMSI H\u8ee2\u79fb\u6027\u7d50\u8178\u30fb\u76f4\u8178\u304c\u3093\u3092\u5bfe\u8c61\u3068\u3057\u305f\u56fd\u969b\u5171\u540c\u7b2c\u2162\u76f8\u8a66\u9a13\u304c\u9032\u884c\u4e2d\u3067\u3059\u3002\u307e\u305f\u3001\u30d8\u30f3\u30ea\u30a2\u30b9\u306f\u3001\u4eca\u5f8c\u3055\u3089\u306b\u304c\u3093\u3092\u9069\u5fdc\u75c7\u3068\u3057\u305f\u958b\u767a\u3092\u8a08\u753b\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u660e\u3089\u304b\u306b\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a \u697d\u5929\u30e1\u30c7\u30a3\u30ab\u30eb\u3068\u30ed\u30c3\u30c6\u30d0\u30a4\u30aa\u30ed\u30b8\u30af\u30b9\u304c\u6226\u7565\u7684\u88fd\u9020\u63d0\u643a\u3092\u7de0\u7d50\u3057\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u63a8\u9032<\/a><\/h4>\n

\u672c\u5951\u7d04\u306b\u57fa\u3065\u304d\u3001\u30a8\u30fc\u30b6\u30a4\u306f\u30bb\u30eb\u30d7\u30ea\u30de\u30d6\u306e\u65e5\u672c\u306b\u304a\u3051\u308b\u72ec\u5360\u7684\u5546\u696d\u5316\u6a29\u3092\u4fdd\u6709\u3057\u307e\u3059\u3002\u30d8\u30f3\u30ea\u30a2\u30b9\u306f\u3001\u65e5\u672c\u306b\u304a\u3051\u308b\u5468\u8853\u671f\u80c3\u304c\u3093\u3092\u5bfe\u8c61\u3068\u3057\u305f\u81e8\u5e8a\u8a66\u9a13\u3092\u4e3b\u5c0e\u3059\u308b\u3068\u3068\u3082\u306b\u3001\u672c\u5264\u306e\u88fd\u9020\u8ca9\u58f2\u627f\u8a8d\u3092\u53d6\u5f97\u3057\u307e\u3059\u3002.<\/p>\n

\u8ca1\u653f\u9762\u3067\u306f\u3001, \u30a8\u30fc\u30b6\u30a4<\/a> \u652f\u6255\u3046 \u30d8\u30f3\u30ea\u30a6\u30b9<\/a> \u5951\u7d04\u4e00\u6642\u91d175\u767e\u4e07\u7c73\u30c9\u30eb\u3002\u672c\u5951\u7d04\u306b\u306f\u3001\u6700\u59278,010\u4e07\u7c73\u30c9\u30eb\u306e\u85ac\u4e8b\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3068\u30012\u51043,330\u4e07\u7c73\u30c9\u30eb\u306b\u9054\u3059\u308b\u53ef\u80fd\u6027\u306e\u3042\u308b\u8ca9\u58f2\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u304c\u542b\u307e\u308c\u307e\u3059\u3002\u307e\u305f\u3001\u30d8\u30f3\u30ea\u30a2\u30b9\u306f\u58f2\u4e0a\u9ad8\u306b\u5fdc\u3058\u30662\u6841\u306e\u30ed\u30a4\u30e4\u30eb\u30c6\u30a3\u3092\u53d7\u3051\u53d6\u308a\u307e\u3059\u3002\u30a8\u30fc\u30b6\u30a4\u306f\u3001\u672c\u5951\u7d04\u304c2026\u5e743\u6708\u671f\u306e\u9023\u7d50\u696d\u7e3e\u4e88\u60f3\u306b\u4e0e\u3048\u308b\u5f71\u97ff\u306f\u306a\u3044\u3068\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>","protected":false},"excerpt":{"rendered":"

Eisai and Shanghai Henlius Biotech have signed an exclusive commercialization agreement and a co exclusive development and manufacturing license agreement for the anti PD 1 monoclonal antibody serplulimab in Japan. The deal gives Eisai the rights to commercialize the drug in the Japanese market, while development and manufacturing responsibilities are shared under the license terms. Serplulimab was developed by Henlius and is positioned as a next generation anti PD 1 antibody. Its binding mechanism is different from existing drugs in the same class. In China, the drug has already received regulatory approval for multiple cancer indications. These include non small cell squamous cell lung cancer, extensive stage small cell lung […]<\/p>\n","protected":false},"author":7,"featured_media":27807,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[11267,1715,11268,346,424],"ppma_author":[572],"class_list":{"0":"post-27806","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-tech","8":"category-international","9":"category-news","10":"category-pharma","11":"tag-anti-pd-1-antibody","12":"tag-eisai","13":"tag-henlius-biotech","14":"tag-manufacturing","15":"tag-pharma"},"yoast_head":"\nEisai and Henlius Secure Japan Rights to Serplulimab<\/title>\n<meta name=\"description\" content=\"Eisai secures Japan commercialization rights to PD-1 antibody serplulimab under a co-development and manufacturing deal with Henlius.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai and Henlius Secure Japan Rights to Serplulimab\" \/>\n<meta property=\"og:description\" content=\"Eisai secures Japan commercialization rights to PD-1 antibody serplulimab under a co-development and manufacturing deal with Henlius.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T10:45:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/Eisai-and-Henlius-enter-into-an-exclusive-commercial-licensing-agreement-for-the-anti-PD-1-antibody-serplulimab-in-Japan.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eisai and Henlius Secure Japan Rights to Serplulimab","description":"Eisai secures Japan commercialization rights to PD-1 antibody serplulimab under a co-development and manufacturing deal with Henlius.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai and Henlius Secure Japan Rights to Serplulimab","og_description":"Eisai secures Japan commercialization rights to PD-1 antibody serplulimab under a co-development and manufacturing deal with Henlius.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/","og_site_name":"itbusinesstoday","article_published_time":"2026-02-06T10:45:37+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/Eisai-and-Henlius-enter-into-an-exclusive-commercial-licensing-agreement-for-the-anti-PD-1-antibody-serplulimab-in-Japan.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Eisai and Henlius Sign Japan Rights Deal for Serplulimab","datePublished":"2026-02-06T10:45:37+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/"},"wordCount":391,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/Eisai-and-Henlius-enter-into-an-exclusive-commercial-licensing-agreement-for-the-anti-PD-1-antibody-serplulimab-in-Japan.webp","keywords":["anti-PD-1 antibody","Eisai","Henlius Biotech","Manufacturing","Pharma"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/","name":"Eisai and Henlius Secure Japan Rights to Serplulimab","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/Eisai-and-Henlius-enter-into-an-exclusive-commercial-licensing-agreement-for-the-anti-PD-1-antibody-serplulimab-in-Japan.webp","datePublished":"2026-02-06T10:45:37+00:00","description":"Eisai secures Japan commercialization rights to PD-1 antibody serplulimab under a co-development and manufacturing deal with Henlius.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/Eisai-and-Henlius-enter-into-an-exclusive-commercial-licensing-agreement-for-the-anti-PD-1-antibody-serplulimab-in-Japan.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/Eisai-and-Henlius-enter-into-an-exclusive-commercial-licensing-agreement-for-the-anti-PD-1-antibody-serplulimab-in-Japan.webp","width":1200,"height":800,"caption":"Eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-henlius-sign-japan-rights-deal-for-serplulimab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Eisai and Henlius Sign Japan Rights Deal for Serplulimab"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/27806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=27806"}],"version-history":[{"count":2,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/27806\/revisions"}],"predecessor-version":[{"id":27843,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/27806\/revisions\/27843"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/27807"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=27806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=27806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=27806"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=27806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}